Antibodies that block PD-L1 prevent the interaction between CD80 and PD-L1 on dendritic cells that are associated with tumors, thereby promoting the anti-tumor immune response mediated by CD80 (93, 101). This evidence concerns the gene CD80 and neoplasm.